Companies / Maze Therapeutics, Inc.

Maze Therapeutics, Inc.

Nasdaq: MAZECIK 1842295SOUTH SAN FRANCISCO, CA

Financials · FY2025

Revenue$167.50M
Net income$-131.12M
Total debt$38.96M
Cash$202.64M
Diluted EPS$-3.05
Shares outstanding55.5M

Ownership

55.5M shares outstanding · as of Aug 5, 2026
0.10%Insiders
Ownership
Insiders0.10%54,581
Institutions91.53%50,843,931
Public float8.37%4,650,656

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 12

View all →
Insider% of sharesShares
Homcy Charles JDirector
0.06%31,113
Bachrodt AmySVP, Finance
0.02%12,965
Dandekar AtulCSBO
0.02%10,503
Bernstein HaroldPresident, R&D & CMO
0.00%0
Sohn Catherine A.Director
0.00%0
Coloma Jason VCEOChief Executive Officer · Director
——
Courtney PhillipsGC and Corp. Secretary
——
Kumar NeilDirector
——
Lim Jonathan EDirector
——
Scheller Richard HDirector
——

Institutional holders 156

View all →
HolderValue% of shares
Frazier Life Sciences Management, L.P.$189.22M8.22%
Trv Gp IV, LLC$185.36M8.05%
Deep Track Capital, LP$175.93M7.64%
ARCH Venture Management, LLC$122.98M7.42%
BlackRock, Inc.$104.52M6.31%
Janus Henderson Group PLC$85.28M5.15%
a16z Capital Management, L.L.C.$70.52M3.06%
Vanguard Group Inc$70.31M3.05%
VR Adviser, LLC$64.16M2.79%
General Catalyst Group Management, LLC$42.92M1.86%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Mar 10, 2026Bernstein Harold
Executive
SellCommon Stock$1.50M-30K
-98.84%
348
<0.01% of shares
medium
Jan 7, 2026Sohn Catherine A.
Director
SellCommon Stock$1.05M-27K
-100.00%
0
0.00% of shares
medium
Jan 7, 2026Bernstein Harold
Executive
SellCommon Stock$1.01M-25K
-100.00%
0
0.00% of shares
medium
Feb 2, 2026Bernstein Harold
Executive
SellCommon Stock$383.8K-8K
-58.08%
6,036
0.01% of shares
medium
Mar 10, 2026Bernstein Harold
Executive
ExerciseCommon Stock$312.6K+30K
30,000
0.05% of shares
low
Mar 20, 2026Bernstein Harold
Executive
SellCommon Stock$297.0K-6K
-41.07%
8,839
0.02% of shares
medium
Feb 2, 2026Bernstein Harold
Executive
SellCommon Stock$275.3K-6K
-98.34%
100
<0.01% of shares
medium
Jan 7, 2026Bernstein Harold
Executive
ExerciseCommon Stock$262.1K+25K
25,156
0.05% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Third Rock Ventures IV, L.P.Passive13G/A———
Gv 2019, L.P.Passive13G/A———
Frazier Life Sciences Public Fund, L.P.Passive13G/A———
Janus Henderson Group PLCPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
MAZE——578784100—